Time Burden of Colon Cancer Treatment

What’s the time burden of colon cancer treatment? How does a diagnosis of colon cancer affect how you spend your personal time or your work time?

Your oncologist can talk to you about your treatment and therapies. Your fellow colon patients and survivors can talk to you about possible side effects and how you may feel while on treatment. But what is the time burden of colon cancer treatment?

The time burden for a newly diagnosed colon cancer patient can be substantial, especially in the first year after diagnosis. It varies by stage, treatment plan, complications, and patient health, but below is a realistic, patient-centered breakdown that reflects what many patients experience.

Colorectal Cancer Surgery Recovery

1. Diagnostic & Staging Phase (First 2–6 weeks)

Estimated time burden: ~20–40 hours total

Common activities

Colonoscopy and pathology review
CT scans (chest/abdomen/pelvis), sometimes MRI or PET
Blood tests (including CEA)
Surgical consultation
Medical oncology consultation
Possibly genetic counseling/testing
Second opinions (common and time-consuming)

Time impact

Multiple half-day medical visits
Waiting time between appointments
Emotional and cognitive load is high during this phase

2. Surgery Phase (if resectable disease)

Preoperative period (1–2 weeks)

Time burden: ~5–10 hours

Pre-op testing, labs, anesthesia visit
Bowel prep and planning

Hospitalization

Time burden: 3–7 days inpatient

Often includes 1–2 days of limited mobility

Recovery

Time burden: ~2–6 weeks

Reduced work capacity
Follow-up visits (1–2)
Possible ostomy education (if applicable)

3. Adjuvant Chemotherapy (Stage II high-risk or Stage III)

Typical duration: 3–6 months
Estimated time burden: ~10–20 hours/month in direct care time

Includes

Infusion visits (every 2–3 weeks or weekly, depending on regimen)
Labs before each cycle
Oncology visits
Pharmacy time
Travel and waiting time

Indirect time burden

Fatigue, neuropathy, GI symptoms
Days of reduced productivity after each cycle
Caregiver time often doubles the true burden

4. Radiation Therapy (less common, mainly rectal cancers)

If needed:

5 days/week for 5–6 weeks
~30–60 minutes per visit
High cumulative travel and fatigue burden

5. Surveillance & Follow-Up (Years 1–3)

Estimated time burden: ~15–25 hours per year

Includes:

Oncology visits every 3–6 months
Routine labs
Annual CT scans
Colonoscopy at 1 year
Management of long-term side effects

6. Administrative & Life Burden (Often Overlooked)

Significant but rarely measured

Insurance approvals and billing issues
Disability/work accommodations
Transportation coordination
Nutrition counseling
Ostomy care (if applicable)
Psychological care and survivorship planning

Approximate Total Time Burden (First Year)

Stage	Estimated Time
Diagnosis & staging	20–40 hours
Surgery & recovery	100–300 hours (including downtime)
Chemotherapy (if needed)	60–120 hours direct care
Follow-up & surveillance	15–25 hours
Total (Year 1)	200–500+ hours

This does not include lost productivity, caregiver time, or emotional labor.

Key Factors That Increase Time Burden

Advanced stage
Postoperative complications
Need for ostomy
Chemotherapy toxicities
Distance to treatment center
Limited social support

Why This Matters

Time burden affects quality of life, employment, finances, and adherence
Patients often underestimate the cumulative impact
Early planning (work leave, caregiver support, telehealth) can reduce stress

I am a long-term survivor of an incurable blood cancer called multiple myeloma. I wish I knew then what I know now.

If you’d like to learn more about evidence-based complementary therapies for managing colon cancer, scroll down the page, post a question or a comment and I will reply to you ASAP.

Hang in there,

David Emerson

Cancer Survivor
Cancer Coach
Director PeopleBeatingCancer

Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal CancerA Nationwide Danish Cohort Study

Key Points

Question What are the colorectal cancer (CRC) stage-specific rates of recurrence and time from surgery to recurrence in patients undergoing surgery with curative intent?

Findings In this cohort study of 34 166 patients with CRC who underwent surgery from 2004 to 2019, the risk of recurrence decreased over time, and higher disease stage was associated with shorter times from surgery to recurrence. Screening-detected CRC was associated with a lower risk of recurrence.

Meaning Findings of this study suggest that the risk of CRC recurrence and the time from surgery to recurrence differ between patient groups, highlighting the importance of further research on risk-stratified surveillance.

Abstract

Importance Management of colorectal cancer (CRC) has been updated continuously over the past 2 decades. While the combination of these initiatives has had implications for improved survival, the implications for rates of recurrence remain unexplored.

Objective To ascertain the rates of recurrence and describe time to recurrence within 5 years of surgery with curative intent for stages I to III CRC.

Design, Setting, and Participants This cohort study used the Danish Colorectal Cancer Group Database to identify patients with Union for International Cancer Control (UICC) stages I to III CRC who underwent primary surgery between January 1, 2004, and December 31, 2019. They were followed up until recurrence (event), death (competing event), diagnosis of a second cancer (competing event), emigration (censoring event), 5 years postoperatively (censoring event), or January 1, 2023 (censoring event), whichever came first. Recurrence status was ascertained through individual-level linked data from the Danish Cancer Registry, Danish National Patient Registry, and Danish Pathology Registry using a validated algorithm. Data were analyzed from January 1 to August 8, 2023.

Exposure Primary surgery performed during 3 calendar periods (2004-2008, 2009-2013, and 2014-2019) stratified by tumor site (colon or rectum) and UICC stage (I, II, and III).

Main Outcomes and Measures Stage-specific 5-year recurrence reported as the cumulative incidence function (CIF) of recurrence, the association between calendar period of primary surgery and recurrence risk reported as subdistribution hazard ratios (sHRs), and the time from surgery to recurrence.

Results Of the 34 166 patients with UICC stages I to III CRC (median [IQR] age, 70 [62-77] years); 18 552 males [54.3%]) included in the study,

7027 developed recurrence within 5 years after the primary surgery. For colon cancer, the 5-year CIF of recurrence decreased over the 3 calendar periods from 16.3% to 6.8% for UICC stage I, from 21.9% to 11.6% for UICC stage II, and from 35.3% to 24.6% for UICC stage III colon cancer.

For rectal cancer, the 5-year CIF decreased over the 3 periods from 19.9% to 9.5% for stage I, from 25.8% to 18.4% for stage II, and from 38.7% to 28.8% for stage III disease. Patients with stage III disease had a shorter time from surgery to recurrence compared with those with stage I disease (time ratio stage III vs stage I = 0.30; 95% CI, 0.28-0.32). Cancers detected through screening were associated with lower stage-adjusted risks of recurrence (sHR, 0.81; 95% CI, 0.73-0.91) compared with cancers not detected through screening.

Conclusions and Relevance In this cohort of patients with CRC, the risk of recurrence decreased in patients with stages I to III disease during the study period. Cancer detection by screening was associated with an even lower risk of recurrence. Time to recurrence differed according to UICC stage. Because the risk of recurrence was so low in selected patient groups, future research is warranted to explore risk-stratified surveillance protocols in patients with CRC.

ime burden of colon cancer treatment ime burden of colon cancer treatment ime burden of colon cancer treatment ime burden of colon cancer treatment?